Angina (Angina Pectoris) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Angina (Angina Pectoris) – Pipeline Review, H2 2016’, provides an overview of the Angina (Angina Pectoris) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Angina (Angina Pectoris), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Angina (Angina Pectoris) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Angina (Angina Pectoris)

The report reviews pipeline therapeutics for Angina (Angina Pectoris) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Angina (Angina Pectoris) therapeutics and enlists all their major and minor projects

The report assesses Angina (Angina Pectoris) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Angina (Angina Pectoris)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Angina (Angina Pectoris)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Angina (Angina Pectoris) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Amgen Inc.

Bayer AG

Juventas Therapeutics, Inc.

Kuhnil Pharmaceutical Co., Ltd.

Lee's Pharmaceutical Holdings Limited

LegoChem Biosciences, Inc

Milestone Pharmaceuticals, Inc.

Sanofi

Shire Plc

Taxus Cardium Pharmaceuticals Group Inc.

ViroMed Co., Ltd.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Angina (Angina Pectoris) Overview 7

Therapeutics Development 8

Pipeline Products for Angina (Angina Pectoris) - Overview 8

Angina (Angina Pectoris) - Therapeutics under Development by Companies 9

Angina (Angina Pectoris) - Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Angina (Angina Pectoris) - Products under Development by Companies 13

Angina (Angina Pectoris) - Companies Involved in Therapeutics Development 14

Amgen Inc. 14

Bayer AG 15

Juventas Therapeutics, Inc. 16

Kuhnil Pharmaceutical Co., Ltd. 17

Lee's Pharmaceutical Holdings Limited 18

LegoChem Biosciences, Inc 19

Milestone Pharmaceuticals, Inc. 20

Sanofi 21

Shire Plc 22

Taxus Cardium Pharmaceuticals Group Inc. 23

ViroMed Co., Ltd. 24

Angina (Angina Pectoris) - Therapeutics Assessment 25

Assessment by Monotherapy Products 25

Assessment by Target 26

Assessment by Mechanism of Action 28

Assessment by Route of Administration 30

Assessment by Molecule Type 32

Drug Profiles 34

alferminogene tadenovec - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

BAY-606583 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

erenumab - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

etripamil - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

JVS-100 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

KI-1007 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

SAR-407899 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Small Molecule to Inhibit Blood Factor XIa for CAHD and Stroke - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Stem Cell Therapy for Cardiovascular Diseases - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

VM-202 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

ZK-001 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Angina (Angina Pectoris) - Dormant Projects 58

Angina (Angina Pectoris) - Discontinued Products 61

Angina (Angina Pectoris) - Product Development Milestones 62

Featured News & Press Releases 62

Sep 12, 2016: Angionetics' Generx Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease 62

May 11, 2015: Angionetics Presents At 2015 Annual Marcum MicroCap Conference On Business And Generx Clinical Development Activities 62

Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum 64

Aug 13, 2014: Cardium Announces Review in Journal Of Cardiovascular Pharmacology Finds Gene Therapy For Subset Of Heart Disease Patients 'Highly Warranted' 66

May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy 67

Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease 69

Jul 07, 2011: Phase Two Study Suggests Use Of Adult Autologous Stem Cells May Improve Cardiac Function In Angina Patients 71

Nov 03, 2010: Cardium Awarded Grant Under QTDP Program 71

Oct 23, 2007: Announcement of supplemental approval of indication of Sigmart Injection, a treatment drug for unstable angina pectoris 72

Appendix 73

Methodology 73

Coverage 73

Secondary Research 73

Primary Research 73

Expert Panel Validation 73

Contact Us 73

Disclaimer 74

List of Tables

List of Tables

Number of Products under Development for Angina (Angina Pectoris), H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Angina (Angina Pectoris) – Pipeline by Amgen Inc., H2 2016 14

Angina (Angina Pectoris) – Pipeline by Bayer AG, H2 2016 15

Angina (Angina Pectoris) – Pipeline by Juventas Therapeutics, Inc., H2 2016 16

Angina (Angina Pectoris) – Pipeline by Kuhnil Pharmaceutical Co., Ltd., H2 2016 17

Angina (Angina Pectoris) – Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 18

Angina (Angina Pectoris) – Pipeline by LegoChem Biosciences, Inc, H2 2016 19

Angina (Angina Pectoris) – Pipeline by Milestone Pharmaceuticals, Inc., H2 2016 20

Angina (Angina Pectoris) – Pipeline by Sanofi, H2 2016 21

Angina (Angina Pectoris) – Pipeline by Shire Plc, H2 2016 22

Angina (Angina Pectoris) – Pipeline by Taxus Cardium Pharmaceuticals Group Inc. , H2 2016 23

Angina (Angina Pectoris) – Pipeline by ViroMed Co., Ltd., H2 2016 24

Assessment by Monotherapy Products, H2 2016 25

Number of Products by Stage and Target, H2 2016 27

Number of Products by Stage and Mechanism of Action, H2 2016 29

Number of Products by Stage and Route of Administration, H2 2016 31

Number of Products by Stage and Molecule Type, H2 2016 33

Angina (Angina Pectoris) – Dormant Projects, H2 2016 58

Angina (Angina Pectoris) – Dormant Projects (Contd..1), H2 2016 59

Angina (Angina Pectoris) – Dormant Projects (Contd..2), H2 2016 60

Angina (Angina Pectoris) – Discontinued Products, H2 2016 61

List of Figures

List of Figures

Number of Products under Development for Angina (Angina Pectoris), H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 25

Number of Products by Targets, H2 2016 26

Number of Products by Stage and Targets, H2 2016 26

Number of Products by Mechanism of Actions, H2 2016 28

Number of Products by Stage and Mechanism of Actions, H2 2016 28

Number of Products by Routes of Administration, H2 2016 30

Number of Products by Stage and Routes of Administration, H2 2016 30

Number of Products by Molecule Types, H2 2016 32

Number of Products by Stage and Molecule Types, H2 2016 32

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports